Skip to main content

Table 1 Clinical and pathological characteristics of patients with estrogen receptor (ER)+ advanced breast cancer according to SNAI2 level

From: SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

  Cohort 1 Cohort 2
Parameters SNAI2 low SNAI2 high Number p a SNAI2 low SNAI2 high Number p a
Age at primary tumor
 ≤ 50 years 8 6 14 0.86 14 7 21 0.11
 > 50 years 43 29 72 20 26 46
Age at metastatic disease
 ≤ 50 years 3 1 4 0.64 7 1 8 0.05
 > 50 years 48 34 82 27 32 59
Size (mm) of primary tumor
 ≤ 20 18 12 30 0.24 12 10 22 0.34
  > 20 to ≤ 50 18 13 31 11 17 28
  > 50 1 4 5 2 2 4
 Unknown 14 6 20 9 4 13
Nodal status of primary tumor
Number of positive lymph nodes
 0 11 10 21 0.46 7 6 13 0.37
 1–3 16 10 26 8 10 18
  > 3 12 11 23 7 11 18
 Unknown 12 4 16 12 6 18
Grade of primary tumor
 I 8 9 17 0.06 6 6 12 0.06
 II 12 15 27 7 16 23
 III 9 2 11 5 1 6
 Unknown 22 9 31 16 10 26
HER2 status of metastasis
 Normal 41 30 71 0.62 29 31 60 0.11
 Amplified 4 1 5 1 2 3
 Unknown 6 4 10 4 0 4
Dominant site of relapse
 Soft tissue 38 23 61 0.65 15 17 32 0.17
 Bone 8 8 16 15 8 23
 Viscera 5 4 9 4 8 12
Total number 51 35 86   34 33 67  
  1. HER2 human epidermal growth factor receptor 2
  2. aχ2 or Fisher’s exact test